Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-stratified sequential ibrutinib and rituximab with optional IR-CHOP for de novo PTLD
2015-005454-35Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib, rituximab, cyclophosphamide, doxorubicin, prednisolone and 1 more in Post-Transplant Lymphoproliferative Disorder (PTLD) (2 arms), sponsored by University of Birmingham. Primary endpoint: Complete remission at 7 weeks. Status: unknown.
02
Drugs
ibrutinibrituximabcyclophosphamidedoxorubicinprednisolone
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on 2015-005454-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005454-35.